CN109419787A - 一种松香烷型二萜类化合物的用途 - Google Patents
一种松香烷型二萜类化合物的用途 Download PDFInfo
- Publication number
- CN109419787A CN109419787A CN201710727168.6A CN201710727168A CN109419787A CN 109419787 A CN109419787 A CN 109419787A CN 201710727168 A CN201710727168 A CN 201710727168A CN 109419787 A CN109419787 A CN 109419787A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- scrodentoid
- purposes according
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 43
- 229930004069 diterpene Natural products 0.000 title claims abstract description 15
- 150000004141 diterpene derivatives Chemical class 0.000 title claims abstract description 15
- 210000003630 histaminocyte Anatomy 0.000 claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 32
- 229940079593 drug Drugs 0.000 claims abstract description 29
- 239000000470 constituent Substances 0.000 claims abstract description 15
- 235000013402 health food Nutrition 0.000 claims abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 239000002243 precursor Substances 0.000 claims abstract description 8
- 239000003381 stabilizer Substances 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 241001530126 Scrophularia Species 0.000 claims description 15
- 235000002226 Ranunculus ficaria Nutrition 0.000 claims description 13
- 238000010828 elution Methods 0.000 claims description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000287 crude extract Substances 0.000 claims description 6
- 239000012043 crude product Substances 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 239000003208 petroleum Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 201000009961 allergic asthma Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 2
- 206010048908 Seasonal allergy Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 39
- 150000002632 lipids Chemical class 0.000 description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 206010022998 Irritability Diseases 0.000 description 9
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000010172 mouse model Methods 0.000 description 9
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- 206010070834 Sensitisation Diseases 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 208000026935 allergic disease Diseases 0.000 description 6
- 239000006184 cosolvent Substances 0.000 description 6
- 108010042617 dinitrophenyl-human serum albumin conjugate Proteins 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- -1 electuary Substances 0.000 description 6
- 230000007815 allergy Effects 0.000 description 5
- 230000003266 anti-allergic effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003337 fertilizer Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 4
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 102000009438 IgE Receptors Human genes 0.000 description 3
- 108010073816 IgE Receptors Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 3
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 108010067755 dinitrophenyl-bovine serum albumin Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000000624 ear auricle Anatomy 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- MFIHSKBTNZNJIK-RZTYQLBFSA-N (3s,3ar,6s,6ar)-3-(3,4-dimethoxyphenyl)-6-(3,4,5-trimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan Chemical compound C1=C(OC)C(OC)=CC=C1[C@@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(OC)=C(OC)C=3)[C@@H]2CO1 MFIHSKBTNZNJIK-RZTYQLBFSA-N 0.000 description 2
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001062009 Indigofera Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 2
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 description 2
- 230000002052 anaphylactic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229960003699 evans blue Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 235000008777 kaempferol Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- VIKNJXKGJWUCNN-FOEMKWDFSA-N (10R,13S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@@H]2C3CC[C@](C)([C@](CC4)(O)C#C)C4C3CCC2=C1 VIKNJXKGJWUCNN-FOEMKWDFSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 239000004229 Alkannin Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001071917 Lithospermum Species 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 101100109871 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aro-8 gene Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100023170 Nuclear receptor subfamily 1 group D member 1 Human genes 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241001050171 Scrophularia dentata Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 235000019232 alkannin Nutrition 0.000 description 1
- 208000037884 allergic airway inflammation Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- MFIHSKBTNZNJIK-UHFFFAOYSA-N medioresinol dimethyl ether Natural products C1=C(OC)C(OC)=CC=C1C1C(COC2C=3C=C(OC)C(OC)=C(OC)C=3)C2CO1 MFIHSKBTNZNJIK-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- XDQITMCFPPPMBC-TUANDBMESA-N scutelloside Natural products OC[C@H]1O[C@@H](O[C@@H]2O[C@@H]3C[C@H]4[C@H](O)[C@@H](O)[C@@](O)(CO3)[C@@H]24)[C@H](O)[C@@H](O)[C@@H]1O XDQITMCFPPPMBC-TUANDBMESA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108010050939 thrombocytin Proteins 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/78—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/78—Separation; Purification; Stabilisation; Use of additives
- C07C45/79—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/78—Separation; Purification; Stabilisation; Use of additives
- C07C45/80—Separation; Purification; Stabilisation; Use of additives by liquid-liquid treatment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种松香烷型二萜类化合物的用途,所述的松香烷型二萜类化合物是具有式Ⅰ所示化学结构:
Description
技术领域
本发明是涉及一种松香烷型二萜类化合物的新用途,属于医药技术领域。
背景技术
过敏,也可称作为过敏性疾病,是由环境中本对人类无害的物质引起的免疫系统的过度反应(McConnell T H.The nature of disease:pathology for the healthprofessions[M].Lippincott Williams&Wilkins,2007)。过敏性疾病常见的主要有花粉症、食物过敏、特应性皮炎以及过敏性哮喘等(Kay A B.Allergy and allergic diseases[J].New England Journal of Medicine,2001,344(1):30-37),其症状主要表现为皮肤红肿、发痒,流涕及呼吸急促等。随着现代工业化进程的发展,过敏已成为世界第六大疾病,正给人们带来持续性的健康威胁。据媒体报道,全球约有22%的人群患有过敏性疾病,其中以儿童患者最多,且患者的数量以每10年23倍的速度持续增长。由此类推,中国正有两亿多人遭受过敏性疾病的困扰。
过敏性疾病的发生过程,可简述为两个阶段,即致敏阶段及激发阶段。致敏阶段:过敏原进入机体后被树突细胞摄入,形成具有免疫原性的抗原肽,并激活树突细胞,使其成熟并迁移至病灶部位。随后树突细胞将其表面的抗原体-MHCⅡ类分子复合物呈递至T细胞。在白介素(IL)4作用下,T细胞发育成为Th2辅助细胞,并分泌IL-4及IL-13,诱导B细胞分泌抗原特异性IgE。IgE可游走于机体全身,并与肥大细胞表面IgE高亲和力受体(FcεRI)结合,使机体处于致敏阶段(Eisenbarth S C,Piggott D A,Huleatt J W,etal.Lipopolysaccharide-enhanced,Toll-like Receptor 4–dependent T Helper CellType 2Responses to Inhaled Antigen[J].Journal of Experimental Medicine,2002,196(12):1645-1651;和Nigo Y I,Nakayama T.Regulation of allergic airwayinflammation through Toll-like receptor 4-mediated modification of mast cellfunction[J].Proceedings of the National Academy of Sciences of the UnitedStates of America,2006,103(7):2286-91)。随后当该过敏原再次进入机体时,过敏原可与两个以上IgE分子结合,使FcεRI发生交联,从而激活肥大细胞,使其发生脱颗粒反应。在脱颗粒过程中,肥大细胞释放的多种介质可使机体支气管扩张,血管舒张、通透性增加并分泌大量粘液物质,最终导致红肿,瘙痒,呕吐,气道阻塞等过敏反应(Metzger H.Thereceptor with high affinity for IgE[J].Immunological reviews,1992,125(1):37-48;和Siraganian R P.Mast cell signal transduction from the high-affinity IgEreceptor[J].Current opinion in immunology,2003,15(6):639-646)。基于上述过程,肥大细胞作为过敏反应的效应器,在过敏反应中起着重要作用。
而在过敏性疾病的治疗方面,目前临床使用的主要为抗组胺药,用药后,易出现困倦、嗜睡、精神不集中等症状。因此,肥大细胞稳定剂成为近来研究热点。
肥大细胞作为免疫系统的一部分,广泛分布于皮肤及粘膜组织周围。IgE激活的肥大细胞脱颗粒过程主要释放三种类型的颗粒物质来发挥其生理功能,分别为:预存介质,如组胺、β-己糖胺酶(β-hex)、血清素、肿瘤坏死因子(TNF)-α等;脂质介质,主要为前列腺素D2及白三烯类物质;以及新合成的介质,包括细胞因子及趋化因子。预存介质中的组胺,作为最为人们所熟知的过敏介质,在肥大细胞被激活后的几分钟内即大量释放,可引起血管扩张,支气管收缩,血管通透性增加以及平滑肌收缩等一系列与过敏及炎症相关的反应(Lundequist A,Pejler G.Biological implications of preformed mast cellmediators[J].Cellular and Molecular Life Sciences,2011,68(6):965-975)。而以前列腺素及白三烯为代表的脂质介质的释放,则是由于细胞内钙流的增加以及MAPK磷酸化引起的,其释放速度较为迅速,仅次于预存介质的释放。脂质介质主要功能为增加机体血管通透性,将免疫效应细胞(如白细胞)募集至病灶部位,促进粘液的产生,以及进一步活化神经细胞。而新合成的介质的释放,则发生于肥大细胞被激活的数小时之后,其可募集免疫效应细胞,并进一步促进炎症的发生(Da Silva E Z M,Jamur M C,Oliver C.Mast CellFunction A New Vision of an Old Cell[J].Journal of Histochemistry&Cytochemistry,2014,62(10):698-738)。因此,研发可抑制肥大细胞活化的药物对预防或/和治疗过敏性非常重要。
天然产物对于新药的发现与设计、合成具有非常重要意义,也是生物活性物质和创新药物的重要来源。目前已经发现多种天然产物具有抗过敏功效,如:槲皮素(Quercetin)、橙皮苷(hesperidin)、山柰酚(Kaempferol)、芍药苷(Paeoniflorin)、黄芩苷(Baicalin)、姜黄素(Curcumin)、紫草素(Shikonin)、木兰脂素(Magnolin)等。我国的中医药学源远流长,博大精深,是中国传统文化的代表与传统文化的瑰宝。因此,从中药中发现新型肥大细胞稳定剂,是抗过敏新药研发的有效途径。
齿叶玄参(Scrophularia dentata Royle ex Benth),为双子叶植物药玄参属植物齿叶玄参的全草,主产于我国西藏地区,具有清热解毒的功效。本发明所述的松香烷型二萜类化合物是具有式Ⅰ所示化学结构:的化合物,是由本申请人首次从齿叶玄参中提取分离得到,在下文中命名为scrodentoid A。目前关于该化合物的用途报道比较少,至今还没有scrodentoid A用于制备抑制肥大细胞脱颗粒的药物的相关报道,更加没有scrodentoid A用于制备肥大细胞稳定剂及用于制备预防或/和治疗因肥大细胞脱颗粒引起的过敏性疾病的药物或保健食品相关报道。
发明内容
针对现有技术存在的上述问题,本发明的目的是提供一种松香烷型二萜类化合物(scrodentoid A)的用途,以拓宽该化合物的应用范围。
本发明所述的松香烷型二萜类化合物,是具有式Ⅰ所示化学结构:
的化合物,本申请中命名为scrodentoid A;所述用途是指以式Ⅰ所示化合物(scrodentoid A)或其水合物、药学上可接受的盐、互变异构体、立体异构体、前体化合物中的至少一种作为活性成分用于制备抑制肥大细胞脱颗粒的药物或保健食品。
作为优选方案,以scrodentoid A或其水合物、药学上可接受的盐、互变异构体、立体异构体、前体化合物中的至少一种作为活性成分用于制备肥大细胞稳定剂。
作为优选方案,以scrodentoid A或其水合物、药学上可接受的盐、互变异构体、立体异构体、前体化合物中的至少一种作为活性成分用于制备预防或/和治疗因肥大细胞脱颗粒引起的过敏性疾病的药物或保健食品。
所述的过敏性疾病包括但不限于:特应性皮炎、花粉症、食物过敏和过敏性哮喘。
所述的scrodentoid A可通过化学合成或从植物中提取得到;作为优选方案,所述的scrodentoid A从玄参属植物齿叶玄参中提取分离得到。
一种实施方案,从玄参属植物齿叶玄参中提取分离scrodentoid A的方法包括如下步骤:
a)以齿叶玄参药材为原料,加乙醇水溶液,进行回流提取2~5次,每次1~6小时;合并滤液,减压浓缩,得流浸膏;将所得流浸膏混悬于水中,以二氯甲烷萃取至萃取液无色;合并萃取液,减压浓缩至浸膏,得到粗提物;
b)将粗提物用硅胶柱层析分离,以石油醚和乙酸乙酯进行梯度洗脱,得到scrodentoid A粗品;
c)将scrodentoid A粗品用MCI柱分离,以甲醇和水进行梯度洗脱;最后用ODS柱分离,也以甲醇和水进行梯度洗脱,即得所述松香烷型二萜类化合物。
作为优选方案,步骤a)中所述的乙醇水溶液的质量分数为50~95%(以95%为佳)。
作为优选方案,步骤a)中每次提取所加入的乙醇水溶液的重量为原料重量的1~10倍。
作为优选方案,步骤b)中用于梯度洗脱的石油醚与乙酸乙酯的体积比按100:0至50:50。
作为优选方案,步骤c)中用于梯度洗脱的甲醇与水的体积比均按75:25至85:15。
本发明所述的药物可以各种给药途径给予患者,包括但不限于口服、透皮、肌肉、皮下和静脉注射。
本发明所述的药物的剂型不限,只要是能够使活性成分有效地到达体内的剂型都可以,包括:片剂、糖衣片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、口含剂、颗粒剂、冲剂、丸剂、散剂、膏剂、丹剂、混悬剂、粉剂、溶液剂、注射剂、栓剂、软膏剂、硬膏剂、霜剂、喷雾剂、滴剂、贴剂等;优选口服剂型,如:胶囊剂、片剂、口服液、颗粒剂、丸剂、散剂、丹剂、膏剂等。
本发明所述药物中,除了含有主要活性成分之外,还可含有少量的且不影响有效成分的次要成分和/或药学上可接受的载体以及各种制剂所必要的辅料等。例如,所述药物为口服剂型时,可含有常用的赋形剂,诸如粘合剂、填充剂、稀释剂、压片剂、润滑剂、崩解剂、着色剂、调味剂和湿润剂,必要时可对片剂进行包衣。适宜的填充剂包括纤维素、甘露糖醇、乳糖和其它类似的填充剂;适宜的崩解剂包括淀粉、聚乙烯吡咯烷酮和淀粉衍生物,例如羟基乙酸淀粉钠;适宜的润滑剂包括,例如硬脂酸镁;适宜的药物可接受的湿润剂包括十二烷基硫酸钠。
本发明中所述术语的定义如下:
术语“药学上可接受的盐”是指所述化合物与药学上可接受的无机酸或有机酸所形成的盐,所述的无机酸包括但不限于:盐酸、氢溴酸、磷酸、硝酸、硫酸;所述的有机酸包括但不限于:甲酸、乙酸、丙酸、丁二酸、1,5-萘二磺酸、亚细亚酸、草酸、酒石酸、乳酸、水杨酸、苯甲酸、戊酸、二乙基乙酸、丙二酸、琥珀酸、富马酸、庚二酸、己二酸、马来酸、苹果酸、氨基磺酸、苯丙酸、葡糖酸、抗坏血酸、烟酸、异烟酸、甲磺酸、对甲苯磺酸、柠檬酸,以及氨基酸;所述“药学上可接受的”是指适用于人而无过度不良副反应(如毒性、刺激和变态反应),即有合理的效益/风险比的物质。
术语“互变异构体”是指因分子中某一原子在两个位置迅速移动而产生的官能团异构体,例如:烯醇与相应的酮。
术语“立体异构体”是指由分子中原子在空间上排列方式不同所产生的异构体,例如:顺反异构体、对映异构体、构象异构体等。
术语“前体化合物”是指在体外无活性,但能够在生物体内进行代谢或化学反应转化为本发明的活性成分,从而发挥其药理作用的化合物。
与现有技术相比,本发明具有如下显著性有益效果:
本发明的研究结果显示:式Ⅰ所示的松香烷型二萜类化合物(scrodentoid A)可显著抑制BMMC细胞中β-己糖胺酶(β-hex),脂质介质(LTC4及PDG2)和炎性因子(TNF-α及IL-6)的释放,说明scrodentoid A可显著抑制肥大细胞脱颗粒;另外,小鼠被动皮肤过敏实验显示,scrodentoid A可以显著抑制小鼠被动皮肤过敏,说明scrodentoid A具有抗过敏作用;因此,式Ⅰ所示的松香烷型二萜类化合物(scrodentoid A)可望作为活性成分用于制备抑制肥大细胞脱颗粒的药物或保健食品,进而可望作为活性成分用于制备肥大细胞稳定剂及用于制备预防或/和治疗因肥大细胞脱颗粒引起的过敏性疾病的药物和保健食品,具有广泛的应用前景。
附图说明
图1体现了scrodentoid A对BMMC细胞中β-hex释放的影响;
图2体现了scrodentoid A对BMMC细胞中LTC4及PDG2释放的影响;
图3体现了scrodentoid A对BMMC细胞中TNF-α及IL-6释放的影响;
图4体现了scrodentoid A对小鼠被动皮肤过敏的影响。
具体实施方式
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件或按照制造厂商所建议的条件。
实施例1:scrodentoid A的制备
a)以齿叶玄参药材为原料,加8倍量95wt%的乙醇水溶液,回流提取3次,每次2小时;合并滤液,减压浓缩,得流浸膏;将所得流浸膏混悬于水中,以二氯甲烷萃取4次;合并萃取液,减压浓缩至浸膏,得到粗提物;
b)将粗提物用硅胶柱层析分离,用石油醚和乙酸乙酯按照体积比为100:0至50:50进行梯度洗脱,TLC薄层分析,收集含有scrodentoid A的流份,减压浓缩,得到scrodentoidA粗品;
c)将scrodentoid A粗品用MCI柱分离,用甲醇和水按照体积比为75:25至85:15进行梯度洗脱,TLC薄层分析,收集所需流分,减压浓缩;浓缩物最后用ODS柱分离,也用甲醇和水按照体积比为75:25至85:15进行梯度洗脱,TLC薄层分析,收集所需流分,减压浓缩,即得所述松香烷型二萜类化合物(HPLC纯度大于99.8%)。
经测试分析得到:分子式为C20H26O2;
表1 scrodentoid A的1HNMR和13CNMR的核磁数据(400MHz,CDCl3,δ,J inHz)
NO. | δ<sub>C</sub>,类型 | δ<sub>H</sub>(J in Hz) | NO. | δ<sub>C</sub>,类型 | δ<sub>H</sub>(J in Hz) |
1 | 37.9,CH<sub>2</sub> | 2.22dt(13.2,3.0);1.74td(13.2,4.0) | 11 | 111.4,CH | 6.79s |
2 | 32.8,CH<sub>2</sub> | 1.39qd(13.0,4.0);1.86br dq,(13.0,3.0) | 12 | 158.7,C | |
3 | 38.2,CH | 2.07m | 13 | 133.3,C | |
4 | 152.1,C | 14 | 127.0,CH | 7.98s | |
5 | 47.6,CH | 2.68m<sup>a</sup> | 15 | 27.1,CH | 3.17sep(6.8) |
6 | 38.3,CH<sub>2</sub> | 2.62m<sup>a</sup>;2.73m<sup>a</sup> | 16 | 20.5,CH<sub>3</sub> | 1.26d(6.8) |
7 | 197.8,C | 17 | 20.6,CH<sub>3</sub> | 1.27d(6.8) | |
8 | 124.6,C | 18 | 105.7,CH<sub>2</sub> | 4.91s;4.69s | |
9 | 154.4,C | 19 | 18.5,CH<sub>3</sub> | 1.11d(6.5) | |
10 | 39.6,C | 20 | 21.3,CH<sub>3</sub> | 1.04s | |
ArOH | 6.23brs |
注:表1中a表示该位置H核磁信号部分重叠。
实施例2:检测肥大细胞中β-hex的释放,分析scrodentoid A(简记为SDA)对肥大细胞β-hex释放的影响
检测scrodentoid A对IgE介导的BMMC细胞释放β-hex的影响:使用BMMC细胞,加入anti-mouse-DNP-IgE过夜后,经药物干预,随后加入DNP-BSA,刺激BMMC细胞发生脱颗粒,检测其β-hex释放量,所有数据均采用mean±SE表示,n=3,*P<0.05,**P<0.01,***P<0.001。
(1)BMMC细胞培养
提取C57BL/6小鼠骨髓,用BMMC细胞专用培养液于37℃,5%CO2培养箱中培养四周。
(2)细胞致敏
BMMC细胞加入0.1μg/ml anti-mouse-DNP-IgE,于37℃,5%CO2培养箱中培养过夜。
(3)加药干预
24h后,加入不同浓度(2.5,5,10,25μM)的scrodentoid A或阳性药(10μM PP2)进行干预30min。
(4)刺激细胞脱颗粒
30min后,加入50ng/ml DNP-HSA刺激30分钟,诱发β-hex的产生和释放。
(5)检测与分析β-hex的释放
取上清液,加入显色液37℃孵育90min,加入甘氨酸终止反应于405nm处检测吸光值,在细胞中加入0.1%的triton-100,使细胞中剩余β-hex的全部释放,根据各种所测OD值计算β-hex释放率(%)。
(6)数据分析
利用软件SPSS16.0进行数据分析,不同干预组的差异性比较采用ANOVA分析,p<0.05认为组间差异具有统计学意义。
(7)实验结果
图1体现了scrodentoid A对BMMC细胞中β-hex释放的影响,由图1可见,与模型组相比,scrodentoid A可以显著抑制BMMC细胞中β-hex释放,且呈浓度依赖性。
实施例3:检测肥大细胞中脂质介质的释放分析scrodentoid A(简记为SDA)对肥大细胞脂质介质释放的影响
检测scrodentoid A对IgE介导的BMMC细胞释放脂质介质的影响:使用BMMC细胞,加入anti-mouse-DNP-IgE过夜后,经药物干预,随后加入DNP-BSA,刺激BMMC细胞释放脂质介质,检测其LTC4及PDG2的释放,所有数据均采用mean±SE表示,n=3,*P<0.05,**P<0.01,***P<0.001。
(1)BMMC细胞培养
提取C57BL/6小鼠骨髓,用BMMC细胞专用培养液于37℃,5%CO2培养箱中培养四周,检测肥大细胞纯度高于99%。
(2)细胞致敏
BMMC细胞加入0.1μg/ml anti-mouse-DNP-IgE,于37℃,5%CO2培养箱中培养过夜。
(3)加药干预
24h后,加入用不同浓度(5,10,25μM)的式I化合物或阳性药(10μM PP2)进行干预30min。
(4)刺激细胞脱颗粒
30min后,加入50ng/ml DNP-HSA刺激30分钟或7小时,诱发脂质介质的产生及释放。
(5)检测与分析LTC4及PDG2的释放
收集各组细胞上清液,根据cayman试剂盒说明书操作,采用ELISA法,检测各组细胞上清液中LTC4及PDG2含量。
(6)数据分析
利用软件SPSS16.0进行数据分析,不同干预组的差异性比较采用ANOVA分析,p<0.05认为组间差异具有统计学意义。
(7)实验结果
图2体现了scrodentoid A对BMMC细胞中LTC4及PDG2释放的影响;其中,图2-a是scrodentoid A对BMMC细胞中LTC4释放的影响;图2-b是scrodentoid A对BMMC细胞中PDG2释放的影响;由图2可见,与模型组相比,scrodentoid A可显著抑制IgE介导的BMMC细胞中LTC4及PDG2的释放,且呈浓度依赖性。
实施例4:检测肥大细胞中炎性介质的释放分析scrodentoid A(简记为SDA)对肥大细胞炎性介质释放的影响
检测scrodentoid A对IgE介导的BMMC细胞释放脂质介质的影响:使用BMMC细胞,加入anti-mouse-DNP-IgE过夜后,经药物干预,随后加入DNP-BSA,刺激BMMC细胞释放脂质介质,检测其TNF-α及IL-6的释放,所有数据均采用mean±SE表示,n=3,*P<0.05,**P<0.01,***P<0.001。
(1)BMMC细胞培养
提取C57BL/6小鼠骨髓,用BMMC细胞专用培养液于37℃,5%CO2培养箱中培养四周。
(2)细胞致敏
BMMC细胞加入0.1μg/ml anti-mouse-DNP-IgE,于37℃,5%CO2培养箱中培养过夜。
(3)加药干预
24h后,加入不同浓度(5,10,25μM)的式I化合物或阳性药(10μM PP2)进行干预30min。
(4)刺激细胞脱颗粒
30min后,加入50ng/ml DNP-HSA刺激24小时,诱发炎性介质的产生及释放。
(5)检测与分析TNF-α及IL-6的释放
收集各组细胞上清液,根据ebioscience试剂盒说明书操作,采用ELISA法,检测各组细胞上清液中TNF-α及IL-6含量。
(6)数据分析
利用软件SPSS16.0进行数据分析,不同干预组的差异性比较采用ANOVA分析,p<0.05认为组间差异具有统计学意义。
(7)实验结果
图3体现了scrodentoid A对BMMC细胞中TNF-α及IL-6释放的影响;其中,图3-a是scrodentoid A对BMMC细胞中TNF-α释放的影响;图3-b是scrodentoid A对BMMC细胞中IL-6释放的影响;由图3可见,与模型组相比,scrodentoid A可显著抑制IgE介导的BMMC细胞中TNF-α及IL-6的释放,且呈浓度依赖性。
由实施例2至4的结果可知:scrodentoid A可显著抑制肥大细胞脱颗粒。
实施例5:scrodentoid A(简记为SDA)对小鼠被动皮肤过敏的影响
检测scrodentoid A(简记为SDA)对小鼠被动皮肤过敏的影响:以雄性ICR小鼠为实验对象,将雄性ICR小鼠随机分为6组,分别为空白组、模型组、低剂量组(25mg/kg)、中剂量组(50mg/kg)、高剂量组(100mg/kg)及阳性药非索那定组(50mg/kg);在各组小鼠右耳注射anti-DNP-IgE 1μg,空白组注射等体积PBS;24小时后,各组灌胃给药不同浓度的scrodentoid A及非索那定,30min后,各组尾静脉注射DNP-HSA(0.5%Evans blue),30min后小鼠脱颈椎处死,取各小鼠右耳浸泡于300μl甲酰胺中,24小时后,离心,取上清液,于630nm处检测吸光度,所有数据均采用mean±SE表示,n=6,*P<0.05,**P<0.01,***P<0.001。
(1)ICR小鼠的饲养
ICR小鼠饲养于屏障系统小鼠实验饲养室(温度:22~23℃,湿度:50~70%,工作照度:150~300Lx,动物照度:15~20Lx,噪声标准<60dB);试验前,适应环境1周。
(2)ICR小鼠的分组
ICR小鼠36只,按体重随机分为6组,每组6只,分别为空白组,模型组,低剂量组(25mg/kg),中剂量组(50mg/kg),高剂量组(100mg/kg)及阳性药非索那定组(50mg/kg),进行药效学实验。
(3)小鼠右耳注射anti-mouse-DNP-IgE
各组小鼠右耳耳廓注射anti-mouse-DNP-IgE 1μg,空白组注射等体积PBS,致敏24小时。
(4)药物处理
非索那定阳性药对照组:将非索那定药物溶解于含有10%助溶剂的双蒸水中,给予50mg/kg/d非索那定;
scrodentoid A低剂量组:将scrodentoid A溶解于含有10%助溶剂的双蒸水中,分别给予25mg/kg/d scrodentoid A;
scrodentoid A中剂量组:将scrodentoid A溶解于含有10%助溶剂的双蒸水中,分别给予50mg/kg/d scrodentoid A;
scrodentoid A高剂量组:将scrodentoid A溶解于含有10%助溶剂的双蒸水中,分别给予100mg/kg/d scrodentoid A;
模型对照组:给予含有10%助溶剂的双蒸水;
空白对照组:给予含有10%助溶剂的双蒸水。
(5)小鼠尾静脉注射DNP-HSA
给药30分钟后,各组尾静脉注射DNP-HSA(0.5%Evans blue),30min后小鼠脱颈椎处死。
(6)小鼠右耳耳廓蓝染检测
取各小鼠右耳浸泡于甲酰胺中,24小时后,离心,取上清液,于630nm处检测吸光度。
图4-a和图4-b体现了scrodentoid A对小鼠被动皮肤过敏的影响;由图4可见,与模型组小鼠相比,scrodentoid A可以显著抑制小鼠右耳耳廓蓝染情况,且呈浓度依赖性,说明scrodentoid A可以显著抑制小鼠被动皮肤过敏,进而说明scrodentoid A具有抗过敏作用。
综上所述:本发明所述的松香烷型二萜类化合物(scrodentoid A)可显著抑制BMMC细胞中β-己糖胺酶(β-hex),脂质介质(LTC4及PDG2)和炎性因子(TNF-α及IL-6)的释放,说明scrodentoid A可显著抑制肥大细胞脱颗粒;另外,小鼠被动皮肤过敏实验显示,scrodentoid A可以显著抑制小鼠被动皮肤过敏,说明scrodentoid A具有抗过敏作用;因此,本发明所述的松香烷型二萜类化合物(scrodentoid A)可望作为活性成分用于制备抑制肥大细胞脱颗粒的药物或保健食品,进而可望作为活性成分用于制备肥大细胞稳定剂及制备预防或/和治疗因肥大细胞脱颗粒引起的过敏性疾病的药物和保健食品,具有广泛的应用前景。
最后需要在此指出的是:以上仅是本发明的部分优选实施例,不能理解为对本发明保护范围的限制,本领域的技术人员根据本发明的上述内容做出的一些非本质的改进和调整均属于本发明的保护范围。
Claims (10)
1.一种松香烷型二萜类化合物的用途,所述的松香烷型二萜类化合物是具有式Ⅰ所示化学结构:的化合物,所述用途是指以式Ⅰ所示化合物或其水合物、药学上可接受的盐、互变异构体、立体异构体、前体化合物中的至少一种作为活性成分用于制备抑制肥大细胞脱颗粒的药物或保健食品。
2.根据权利要求1所述的用途,其特征在于:以式Ⅰ所示化合物或其水合物、药学上可接受的盐、互变异构体、立体异构体、前体化合物中的至少一种作为活性成分用于制备肥大细胞稳定剂。
3.根据权利要求1所述的用途,其特征在于:以式Ⅰ所示化合物或其水合物、药学上可接受的盐、互变异构体、立体异构体、前体化合物中的至少一种作为活性成分用于制备预防或/和治疗因肥大细胞脱颗粒引起的过敏性疾病的药物或保健食品。
4.根据权利要求3所述的用途,其特征在于,所述过敏性疾病包括但不限于:特应性皮炎、花粉症、食物过敏和过敏性哮喘。
5.根据权利要求1至3中任一项所述的用途,其特征在于:式Ⅰ所示化合物是从玄参属植物齿叶玄参中提取分离得到。
6.根据权利要求5所述的用途,其特征在于,从玄参属植物齿叶玄参中提取分离式Ⅰ所示化合物的方法包括如下步骤:
a)以齿叶玄参药材为原料,用乙醇水溶液进行回流提取2~5次,每次1~6小时;合并滤液,减压浓缩,得流浸膏;将所得流浸膏混悬于水中,以二氯甲烷萃取至萃取液无色;合并萃取液,减压浓缩至浸膏,得到粗提物;
b)将粗提物用硅胶柱层析分离,以石油醚和乙酸乙酯进行梯度洗脱,得到式Ⅰ所示化合物的粗品;
c)将步骤b)所得粗品用MCI柱分离,以甲醇和水进行梯度洗脱;最后用ODS柱分离,也以甲醇和水进行梯度洗脱,即得式Ⅰ所示化合物。
7.根据权利要求6所述的用途,其特征在于:步骤a)中所述的乙醇水溶液的质量分数为50~95%。
8.根据权利要求6所述的用途,其特征在于:步骤a)中每次提取所加入的乙醇水溶液的重量为原料重量的1~10倍。
9.根据权利要求6所述的用途,其特征在于:步骤b)中用于梯度洗脱的石油醚与乙酸乙酯的体积比按100:0至50:50。
10.根据权利要求6所述的用途,其特征在于:步骤c)中用于梯度洗脱的甲醇与水的体积比均按75:25至85:15。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710727168.6A CN109419787B (zh) | 2017-08-23 | 2017-08-23 | 一种松香烷型二萜类化合物的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710727168.6A CN109419787B (zh) | 2017-08-23 | 2017-08-23 | 一种松香烷型二萜类化合物的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109419787A true CN109419787A (zh) | 2019-03-05 |
CN109419787B CN109419787B (zh) | 2020-11-06 |
Family
ID=65497965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710727168.6A Active CN109419787B (zh) | 2017-08-23 | 2017-08-23 | 一种松香烷型二萜类化合物的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109419787B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111557931A (zh) * | 2020-06-15 | 2020-08-21 | 上海中医药大学 | 玄参萜酮a的新用途 |
CN116585301A (zh) * | 2023-07-18 | 2023-08-15 | 青岛瑞源细胞生物科技开发有限公司 | 一种提高干细胞治疗能力的制剂 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104557823A (zh) * | 2013-10-15 | 2015-04-29 | 上海中医药大学 | 松香型二萜衍生物及其制备方法和应用 |
CN106632378A (zh) * | 2016-12-23 | 2017-05-10 | 上海中医药大学 | 一种可抑制肥大细胞脱颗粒的化合物及其制备方法和用途 |
-
2017
- 2017-08-23 CN CN201710727168.6A patent/CN109419787B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104557823A (zh) * | 2013-10-15 | 2015-04-29 | 上海中医药大学 | 松香型二萜衍生物及其制备方法和应用 |
CN106632378A (zh) * | 2016-12-23 | 2017-05-10 | 上海中医药大学 | 一种可抑制肥大细胞脱颗粒的化合物及其制备方法和用途 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111557931A (zh) * | 2020-06-15 | 2020-08-21 | 上海中医药大学 | 玄参萜酮a的新用途 |
CN116585301A (zh) * | 2023-07-18 | 2023-08-15 | 青岛瑞源细胞生物科技开发有限公司 | 一种提高干细胞治疗能力的制剂 |
CN116585301B (zh) * | 2023-07-18 | 2023-09-22 | 青岛瑞源细胞生物科技开发有限公司 | 一种提高干细胞治疗能力的制剂 |
Also Published As
Publication number | Publication date |
---|---|
CN109419787B (zh) | 2020-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10624938B2 (en) | Total flavone extract of flower of abelmoschus manihot L. medic and preparation method thereof | |
CN105997985A (zh) | 一种大麻提取物在制备治疗痛风药物中的应用 | |
KR101544804B1 (ko) | 면역장애로부터 유발된 질환을 치료하기 위한 약학적 조성물 및 복령 추출물 | |
TW201618801A (zh) | 用於輔助化療藥物之醫藥組合物及其用途 | |
CN109419787A (zh) | 一种松香烷型二萜类化合物的用途 | |
CN106831679B (zh) | 新党参炔醇类化合物及其制备方法、应用和其药物组合物 | |
WO2003025155A1 (fr) | Produit de fermentation de cryptoporus volvatus et son procede de preparation et utilisation | |
KR101051076B1 (ko) | 개복숭아를 포함하는 알레르기 치료용 조성물 및 이의 제조방법 | |
RU2651750C2 (ru) | Применение экстракта albizzia chinensis для получения лекарственного средства для лечения язвы желудка | |
WO2022143514A1 (zh) | 含有咖啡酸酯和灯盏花素的口服制剂及其制备方法 | |
CN109820947A (zh) | 一种中药组合物在制备治疗上气道咳嗽综合征药物中的应用 | |
KR101160249B1 (ko) | 자라 추출물을 함유하는 피부질환의 개선 또는 치료용 약학적 조성물 | |
KR101119410B1 (ko) | 회향근 추출물을 유효성분으로 포함하는 염증성 질환 치료 및 예방용 조성물 | |
CN106632378A (zh) | 一种可抑制肥大细胞脱颗粒的化合物及其制备方法和用途 | |
CN109303785B (zh) | 一种党参炔苷类似化合物在制备治疗心率失常药物中的应用 | |
KR20210058760A (ko) | 대추나무 뿌리 추출물을 포함하는 신장 질환의 예방 또는 치료용 조성물 | |
CN113577158A (zh) | 一种治疗急性肺损伤的衢枳壳有效成分组及其制备方法与应用 | |
CN105497167A (zh) | 猫爪草在制备治疗和/或预防溃疡性结肠炎药物方面的新用途 | |
KR101334264B1 (ko) | 거북 추출물을 함유하는 피부질환의 개선 또는 치료용 약학적 조성물 | |
KR20190075850A (ko) | 김 추출물을 함유하는 가려움증의 개선, 예방 또는 치료용 조성물 | |
CN104958305A (zh) | 治疗免疫失调所引起的疾病的医药组合物及茯苓萃取物 | |
CN104435068B (zh) | 一种具有减肥作用的杜仲组合物及其制剂 | |
KR102499893B1 (ko) | 삼백초 분획물을 포함하는 약학 조성물 및 이의 제조 방법 | |
CN116120389B (zh) | 人参皂苷Rg5及制备和在制备过敏性鼻炎药物中的应用 | |
CN101406498A (zh) | 一种桂花降血糖有效部位及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |